Skip to content
Screener

Ironwood Pharmaceuticals IRWD Q3 2025 earnings

Reported November 10, 2025 · Before market open

Revenue$122.1MBeat by $71.1M
EPS$0.24Beat by $0.15
Revenue estimate$50.9M
EPS estimate$0.09

Next report

Nov 9, 2026 (in 2 months)
Revenue estimate$120.0M
EPS estimate$0.30

Financials

Q3 2025

Income statement

See full
Revenue$122.1M+33.3%
Operating income$75.5M+194%
Net income$40.1M+999%
EPS (diluted)$0.23+1,050%

Balance sheet

See full
Cash & equivalents$140.4M+59.2%
Total debt$213.2M+1,228%
Total equity-$264.2M+15.2%
Total assets$396.1M+1.7%

Cash flow

See full
Operating cash flow$47.6M+381%
CapEx$2.0K-87.5%
Free cash flow$47.6M+382%

Valuation & ratios

Valuation

as of 09/30/25
See full
Market cap$212.79M-67.5%
Enterprise value$285.62M-51.0%
P/E7.5×—
P/S0.6×-1.1×

Profitability

See full
Operating margin36.3%+20.1pp
Net margin8.4%+7.9pp

Returns & leverage

See full
Current ratio1.1×-2.5×

Segments

By product

See full
Royalty$900.0K+12.5%
Collaborative Arrangement Development And Commercialization Agreements$200.0K-68.4%

FAQ

When did Ironwood Pharmaceuticals report Q3 2025 earnings?
Ironwood Pharmaceuticals (IRWD) reported Q3 2025 earnings on November 10, 2025 before market open.
What were Ironwood Pharmaceuticals's Q3 2025 revenue and EPS?
Ironwood Pharmaceuticals reported revenue of $122.1M and eps of $0.24 for Q3 2025.
Did Ironwood Pharmaceuticals beat estimates in Q3 2025?
Revenue beat the consensus estimate of $50.9M by $71.1M. EPS beat the consensus estimate of $0.09 by $0.15.
How did Ironwood Pharmaceuticals's Q3 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 33.3% from $91.6M a year earlier and eps grew 1100.0% from $0.02.
Where can I find Ironwood Pharmaceuticals's Q3 2025 SEC filings?
You can read the 8-K earnings release (0001104659-25-108806) and the 10-Q periodic report (0001104659-25-108795) directly on SEC EDGAR. The filing index links above go to sec.gov.